Ghent University Academic Bibliography

Advanced

Further pharmacological and genetic evidence for the efficacy of PlGF inhibition in cancer and eye disease

Sara Van de Veire, Ingeborg Stalmans, Femke Heindryckx UGent, Hajimu Oura, Annemilai Tijeras-Raballand, Thomas Schmidt, Sonja Loges, Imke Albrecht, Bart Jonckx and Stefan Vinckier, et al. (2010) CELL. 141(1). p.178-190
abstract
Our findings that PlGF is a cancer target and anti-PlGF is useful for anticancer treatment have been challenged by Bais et al. Here we take advantage of carcinogen-induced and transgenic tumor models as well as ocular neovascularization to report further evidence in support of our original findings of PlGF as a promising target for anticancer therapies. We present evidence for the efficacy of additional anti-PlGF antibodies and their ability to phenocopy genetic deficiency or silencing of PlGF in cancer and ocular disease but also show that not all anti-PlGF antibodies are effective. We also provide additional evidence for the specificity of our anti-PlGF antibody and experiments to suggest that anti-PlGF treatment will not be effective for all tumors and why. Further, we show that PlGF blockage inhibits vessel abnormalization rather than density in certain tumors while enhancing VEGF-targeted inhibition in ocular disease. Our findings warrant further testing of anti-PlGF therapies.
Please use this url to cite or link to this publication:
author
organization
year
type
journalArticle (original)
publication status
published
subject
keyword
HYPOXIA, LUNG, HEPATOCELLULAR-CARCINOMA, PLACENTA GROWTH-FACTOR, PATHOLOGICAL CONDITIONS, MOUSE MODEL, METASTASIS, ANGIOGENESIS, PROGRESSION, MICE
journal title
CELL
Cell
volume
141
issue
1
pages
13 pages
Web of Science type
Article
Web of Science id
000276211100022
JCR category
BIOCHEMISTRY & MOLECULAR BIOLOGY
JCR impact factor
32.401 (2010)
JCR rank
1/284 (2010)
JCR quartile
1 (2010)
ISSN
0092-8674
DOI
10.1016/j.cell.2010.02.039
language
English
UGent publication?
yes
classification
A1
copyright statement
I have transferred the copyright for this publication to the publisher
id
931075
handle
http://hdl.handle.net/1854/LU-931075
date created
2010-04-19 12:07:04
date last changed
2012-06-26 14:32:00
@article{931075,
  abstract     = {Our findings that PlGF is a cancer target and anti-PlGF is useful for anticancer treatment have been challenged by Bais et al. Here we take advantage of carcinogen-induced and transgenic tumor models as well as ocular neovascularization to report further evidence in support of our original findings of PlGF as a promising target for anticancer therapies. We present evidence for the efficacy of additional anti-PlGF antibodies and their ability to phenocopy genetic deficiency or silencing of PlGF in cancer and ocular disease but also show that not all anti-PlGF antibodies are effective. We also provide additional evidence for the specificity of our anti-PlGF antibody and experiments to suggest that anti-PlGF treatment will not be effective for all tumors and why. Further, we show that PlGF blockage inhibits vessel abnormalization rather than density in certain tumors while enhancing VEGF-targeted inhibition in ocular disease. Our findings warrant further testing of anti-PlGF therapies.},
  author       = {Van de Veire, Sara and Stalmans, Ingeborg and Heindryckx, Femke and Oura, Hajimu and Tijeras-Raballand, Annemilai and Schmidt, Thomas and Loges, Sonja and Albrecht, Imke and Jonckx, Bart and Vinckier, Stefan and Van Steenkiste, Christophe and Tugues, Sonia and Rolny, Charlotte and De Mol, Maria and Dettori, Daniela and Hainaud, Patricia and Coenegrachts, Lieve and Contreres, Jean-Olivier and Van Bergen, Tine and Cuervo, Henar and Xiao, Wei-Hong and Le Henaff, Carole and Buysschaert, Ian and Masouleh, Bezad Kharabi and Geerts, Anja and Schomber, Tibor and Bonnin, Philippe and Lambert, Vincent and Haustraete, Jurgen and Zacchigna, Serena and Rakic, Jean-Marie and Jimenez, Wladimiro and Noel, Agnes and Giacca, Mauro and Colle, Isabelle and Foidart, Jean-Michel and Tobelem, Gerard and Morales-Ruiz, Manuel and Vilar, Jose and Maxwell, Patrick and Vinores, Stanley A and Carmeliet, Geert and Dewerchin, Mieke and Claesson-Welsh, Lena and Dupuy, Evelyne and Van Vlierberghe, Hans and Christofori, Gerhard and Mazzone, Massimiliano and Detmar, Michael and Collen, Desire and Carmeliet, Peter},
  issn         = {0092-8674},
  journal      = {CELL},
  keyword      = {HYPOXIA,LUNG,HEPATOCELLULAR-CARCINOMA,PLACENTA GROWTH-FACTOR,PATHOLOGICAL CONDITIONS,MOUSE MODEL,METASTASIS,ANGIOGENESIS,PROGRESSION,MICE},
  language     = {eng},
  number       = {1},
  pages        = {178--190},
  title        = {Further pharmacological and genetic evidence for the efficacy of PlGF inhibition in cancer and eye disease},
  url          = {http://dx.doi.org/10.1016/j.cell.2010.02.039},
  volume       = {141},
  year         = {2010},
}

Chicago
Van de Veire, Sara, Ingeborg Stalmans, Femke Heindryckx, Hajimu Oura, Annemilai Tijeras-Raballand, Thomas Schmidt, Sonja Loges, et al. 2010. “Further Pharmacological and Genetic Evidence for the Efficacy of PlGF Inhibition in Cancer and Eye Disease.” Cell 141 (1): 178–190.
APA
Van de Veire, S., Stalmans, I., Heindryckx, F., Oura, H., Tijeras-Raballand, A., Schmidt, T., Loges, S., et al. (2010). Further pharmacological and genetic evidence for the efficacy of PlGF inhibition in cancer and eye disease. CELL, 141(1), 178–190.
Vancouver
1.
Van de Veire S, Stalmans I, Heindryckx F, Oura H, Tijeras-Raballand A, Schmidt T, et al. Further pharmacological and genetic evidence for the efficacy of PlGF inhibition in cancer and eye disease. CELL. 2010;141(1):178–90.
MLA
Van de Veire, Sara, Ingeborg Stalmans, Femke Heindryckx, et al. “Further Pharmacological and Genetic Evidence for the Efficacy of PlGF Inhibition in Cancer and Eye Disease.” CELL 141.1 (2010): 178–190. Print.